Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Mergers & Acquisitions
Ginkgo Bioworks acquires 3 companies
By
LabPulse.com staff writers
Ginkgo Bioworks has acquired three startups: gene-editing diagnostics developer Proof Diagnostics, artificial intelligence (AI)-driven drug discovery company Reverie Labs, and AI platform developer Patch Biosciences.
February 29, 2024
Bruker enters agreement to acquire ELITechGroup
By
LabPulse.com staff writers
Life sciences and diagnostics firm Bruker has entered into a definitive share purchase agreement with Paris-based private equity firm PAI Partners to acquire molecular diagnostics firm ELITechGroup, excluding its ELITech clinical chemistry business.
February 28, 2024
German regulatory agency opens review of Thermo Fisher, Olink deal
By
LabPulse.com staff writers
Germany’s antitrust regulatory agency, the Bundeskartellamt, has moved into a phase II review of Thermo Fisher’s acquisition of Swedish proteomics firm Olink.
February 22, 2024
Bruker eyes Chemspeed to accelerate entry into lab automation market
By
LabPulse.com staff writers
Basel, Switzerland-based Bruker announced that it plans to acquire Chemspeed to accelerate Bruker’s entry into the lab automation, digitalization, and scientific software solutions market.
February 2, 2024
Invitae sells reproductive health assets to Natera
By
LabPulse.com staff writers
Invitae on Monday has completed the sale of some of its reproductive health assets, including carrier screening and noninvasive prenatal screening, to Natera.
January 22, 2024
Steward offloads outreach laboratory services business
By
LabPulse.com staff writers
Quest Diagnostics has acquired select assets of outreach laboratory services in Pennsylvania and Ohio from Steward Health Care System, a large, private, and fully-integrated for-profit system based in Dallas.
January 9, 2024
Tome Biosciences acquires Replace Therapeutics in $65M deal
By
LabPulse.com staff writers
Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.
January 5, 2024
Roche signs $350M deal to buy POC technology from LumiraDx
By
LabPulse.com staff writers
Roche has entered into a definitive agreement to purchase point-of care (POC) technologies from LumiraDx for $295 million, with an additional payment of up to $55 million to fund the POC diagnostics platform business until the transaction closes.
January 3, 2024
Bristol Myers Squibb to acquire RayzeBio for $4.1B
By
LabPulse.com staff writers
In its second multibillion-dollar acquisition announced within a week, Bristol Myers Squibb will acquire RayzeBio, which develops radiopharmaceutical cancer therapeutics, in an agreement worth approximately $4.1 billion.
December 27, 2023
Bristol Myers Squibb acquires Karuna for $14B
By
LabPulse.com staff writers
Bristol Myers Squibb has made an agreement to buy biotech firm Karuna Therapeutics for $14 billion, an acquisition that gives the firm a promising experimental treatment for schizophrenia.
December 22, 2023
Illumina to divest Grail, will not further appeal FTC order
By
LabPulse.com staff writers
Illumina has said in a statement that it will not pursue further appeals, and will sell Grail “consistent with the European Commission's divestiture order, with the goal of finalizing the terms by the end of the second quarter of 2024.”
December 18, 2023
AstraZeneca to buy Icosavax in agreement worth up to $1.1B
By
LabPulse.com staff writers
AstraZeneca has agreed to buy vaccine developer Icosavax in a deal worth up to $1.1 billion.
December 13, 2023
Page 1 of 11
Next Page